CHANGMAO BIO (0954.HK)
- Previous Close
0.280 - Open
0.295 - Bid 0.285 x --
- Ask 0.315 x --
- Day's Range
0.290 - 0.295 - 52 Week Range
0.255 - 0.500 - Volume
244,000 - Avg. Volume
348,813 - Market Cap (intraday)
148.316M - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.140 - Earnings Date Mar 24, 2025 - Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 22, 2023
- 1y Target Est
--
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, America, and internationally. The company offers fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, medical intermediaries, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. It is also involved in the research and development of medicine and nutraceutical products; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou City, the People's Republic of China.
changmaobio.todayir.com571
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0954.HK
View MorePerformance Overview: 0954.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0954.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0954.HK
View MoreValuation Measures
Market Cap
153.61M
Enterprise Value
649.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
0.25
Enterprise Value/Revenue
1.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-11.67%
Return on Assets (ttm)
-2.83%
Return on Equity (ttm)
-11.05%
Revenue (ttm)
584.79M
Net Income Avi to Common (ttm)
-68.24M
Diluted EPS (ttm)
-0.140
Balance Sheet and Cash Flow
Total Cash (mrq)
74.56M
Total Debt/Equity (mrq)
91.91%
Levered Free Cash Flow (ttm)
-36.14M